arotinolol has been researched along with Obesity in 1 studies
arotinolol: structure given in first source; arotinolol is the (+-)-isomer
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshida, T | 1 |
| Sakane, N | 1 |
| Wakabayashi, Y | 1 |
| Yoshioka, K | 1 |
| Umekawa, T | 1 |
| Kondo, M | 1 |
1 other study available for arotinolol and Obesity
| Article | Year |
|---|---|
The alpha/beta-adrenergic receptor blocker arotinolol activates the thermogenesis of brown adipose tissue in monosodium-L-glutamate-induced obese mice.
Topics: Adipose Tissue; Adipose Tissue, Brown; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; An | 1994 |